CO2018001264A2 - Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos - Google Patents
Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estosInfo
- Publication number
- CO2018001264A2 CO2018001264A2 CONC2018/0001264A CO2018001264A CO2018001264A2 CO 2018001264 A2 CO2018001264 A2 CO 2018001264A2 CO 2018001264 A CO2018001264 A CO 2018001264A CO 2018001264 A2 CO2018001264 A2 CO 2018001264A2
- Authority
- CO
- Colombia
- Prior art keywords
- baff
- activating factor
- compound targeting
- lymphocyte activating
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562196170P | 2015-07-23 | 2015-07-23 | |
| US201562201067P | 2015-08-04 | 2015-08-04 | |
| US201662355302P | 2016-06-27 | 2016-06-27 | |
| PCT/US2016/043267 WO2017015433A2 (en) | 2015-07-23 | 2016-07-21 | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018001264A2 true CO2018001264A2 (es) | 2018-05-10 |
Family
ID=57835236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0001264A CO2018001264A2 (es) | 2015-07-23 | 2018-02-07 | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10280231B2 (https=) |
| EP (1) | EP3322436A4 (https=) |
| JP (1) | JP6866345B2 (https=) |
| KR (1) | KR102644875B1 (https=) |
| CN (1) | CN108135976B (https=) |
| AU (1) | AU2016297575B2 (https=) |
| CL (1) | CL2018000182A1 (https=) |
| CO (1) | CO2018001264A2 (https=) |
| EA (1) | EA201890360A1 (https=) |
| IL (1) | IL256665B2 (https=) |
| MX (1) | MX2018000959A (https=) |
| MY (1) | MY191081A (https=) |
| PE (1) | PE20180774A1 (https=) |
| PH (2) | PH12021552628A1 (https=) |
| SA (1) | SA518390788B1 (https=) |
| SG (1) | SG10201912593VA (https=) |
| TW (2) | TWI733685B (https=) |
| UA (1) | UA125433C2 (https=) |
| WO (1) | WO2017015433A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
| EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| AU2016215535B2 (en) | 2015-02-04 | 2021-09-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| WO2017015433A2 (en) * | 2015-07-23 | 2017-01-26 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TW202535466A (zh) | 2019-09-09 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-il-23p19抗體調配物 |
| CN117916273A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
| WO2024140930A1 (en) * | 2022-12-28 | 2024-07-04 | Suzhou Transcenta Therapeutics Co., Ltd. | Bispecific binding protein comprising anti-baff antibody and use thereof |
| CN121152636A (zh) * | 2023-07-06 | 2025-12-16 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法 |
| WO2025170982A2 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2026008004A1 (zh) * | 2024-07-04 | 2026-01-08 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法 |
| CN119638823A (zh) * | 2024-12-10 | 2025-03-18 | 中国医学科学院病原生物学研究所 | 检测a35r蛋白的单克隆抗体及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (ja) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | 抗腫瘍剤包埋リポソ−ム製剤 |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| KR101759457B1 (ko) | 2007-12-21 | 2017-07-31 | 메디뮨 리미티드 | 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173 |
| EP2116556B1 (en) * | 2008-05-09 | 2016-03-23 | AbbVie Deutschland GmbH & Co KG | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| GB201002238D0 (en) * | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
| EP4012714A1 (en) | 2010-03-23 | 2022-06-15 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| AU2011286024B2 (en) | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| MX2019000046A (es) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anticuerpos anti-il-23. |
| GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
| US9505826B2 (en) * | 2010-12-22 | 2016-11-29 | Teva Pharmaceuticals Australia Pty Ltd | Modified antibody with improved half-life |
| EP2686345B1 (en) * | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| MX360352B (es) | 2012-02-15 | 2018-10-30 | Hoffmann La Roche | Cromatografia de afinidad basada en receptores fc. |
| GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| AR090626A1 (es) | 2012-04-20 | 2014-11-26 | Lilly Co Eli | Anticuerpos anti-baff-anti-il-17 biespecificos |
| US8945553B2 (en) | 2012-05-22 | 2015-02-03 | Bristol-Myers Squibb Company | Bispecific antibodies to IL-23 and IL-17A/F |
| KR102181776B1 (ko) * | 2012-06-05 | 2020-11-24 | 삼성전자주식회사 | 범용 디바이스에서의 파일 송/수신 장치 및 방법 |
| EP2934577A1 (en) | 2012-12-19 | 2015-10-28 | Adimab, LLC | Multivalent antibody analogs, and methods of their preparation and use |
| JP2015088330A (ja) * | 2013-10-30 | 2015-05-07 | トヨタ自動車株式会社 | 硫黄含有全固体電池 |
| WO2015100246A1 (en) * | 2013-12-24 | 2015-07-02 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| EA033604B1 (ru) * | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
| WO2017015433A2 (en) * | 2015-07-23 | 2017-01-26 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and b-cell activating factor (baff) and uses thereof |
-
2016
- 2016-07-21 WO PCT/US2016/043267 patent/WO2017015433A2/en not_active Ceased
- 2016-07-21 SG SG10201912593VA patent/SG10201912593VA/en unknown
- 2016-07-21 MX MX2018000959A patent/MX2018000959A/es unknown
- 2016-07-21 US US15/215,690 patent/US10280231B2/en active Active
- 2016-07-21 IL IL256665A patent/IL256665B2/en unknown
- 2016-07-21 TW TW105123026A patent/TWI733685B/zh active
- 2016-07-21 PH PH1/2021/552628A patent/PH12021552628A1/en unknown
- 2016-07-21 TW TW110122529A patent/TWI861413B/zh active
- 2016-07-21 CN CN201680051316.0A patent/CN108135976B/zh active Active
- 2016-07-21 PE PE2018000111A patent/PE20180774A1/es unknown
- 2016-07-21 KR KR1020187004892A patent/KR102644875B1/ko active Active
- 2016-07-21 JP JP2018503151A patent/JP6866345B2/ja active Active
- 2016-07-21 AU AU2016297575A patent/AU2016297575B2/en active Active
- 2016-07-21 UA UAA201801854A patent/UA125433C2/uk unknown
- 2016-07-21 EP EP16828518.7A patent/EP3322436A4/en active Pending
- 2016-07-21 MY MYPI2018000034A patent/MY191081A/en unknown
- 2016-07-21 EA EA201890360A patent/EA201890360A1/ru unknown
-
2018
- 2018-01-18 PH PH12018500151A patent/PH12018500151A1/en unknown
- 2018-01-22 CL CL2018000182A patent/CL2018000182A1/es unknown
- 2018-01-23 SA SA518390788A patent/SA518390788B1/ar unknown
- 2018-02-07 CO CONC2018/0001264A patent/CO2018001264A2/es unknown
-
2019
- 2019-02-18 US US16/278,216 patent/US10844138B2/en active Active
-
2020
- 2020-10-22 US US17/076,894 patent/US11884744B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018001264A2 (es) | Compuesto que se dirige a il-23a y al factor de activación de linfocitos b (baff) y usos de estos | |
| CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
| CL2025001440A1 (es) | Medios y método para preparar vectores virales y usos de los mismos | |
| CL2017002155A1 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| CL2017003258A1 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2018000194A1 (es) | Compuestos de piridina | |
| ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
| CO2018002196A2 (es) | Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas | |
| UY35467A (es) | Compuestos orgánicos | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| CL2017003107A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| CU20180027A7 (es) | DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| UY35796A (es) | ?derivados de dihidrohidantoína sustituidos, procesos para prepararlos, composiciones herbicidas y su uso en plantas?. | |
| CO2019006687A2 (es) | Polimorfos | |
| MX2016004565A (es) | Preparacion de derivados de hidroxi - bencilbenceno. | |
| CR20160224A (es) | Composición herbicida que comprende inhibidores ACC | |
| PY1735113A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos |